GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to tackle stomach cancer relapse
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significan…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cocktail of drugs shows promise for stomach cancer patients
Disease control Not yet recruitingThis phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ming Liu • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heated chemo cocktail may boost immune attack on stomach cancer
Disease control Not yet recruitingThis study tests a new approach for people with locally advanced stomach cancer that has not spread to other organs. First, patients receive heated chemotherapy directly into the abdomen to kill any hidden cancer cells. Then they get an immunotherapy drug (serplulimab) combined w…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus injected into tumors before surgery: a new hope?
Disease control Not yet recruitingThis study tests whether injecting a virus called RP2 directly into stomach and esophageal tumors, combined with standard FLOT chemotherapy, is safe and works better than chemotherapy alone before surgery. About 34 people with stage II or higher non-metastatic gastroesophageal ca…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New triple therapy targets stomach cancer after immunotherapy fails
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—retlirafusp alfa, apatinib, and nab-paclitaxel—in 50 adults with advanced stomach or gastroesophageal junction cancer that has progressed after first-line immunotherapy. The goal is to see if the combination can shrink tumors …
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to shrink advanced stomach tumors
Disease control Not yet recruitingThis study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Tailored therapy after stomach cancer surgery could boost survival
Disease control Not yet recruitingThis study looks at whether changing the type of chemotherapy after stomach cancer surgery can help people live longer. It involves 405 adults who had chemotherapy and immunotherapy before surgery. Depending on how much cancer remained after surgery, some will get a different tre…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Triple threat: new combo therapy targets Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis clinical trial is testing a new approach for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) and a…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE4 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for advanced stomach cancer: drug combo plus radiation shows promise
Disease control Not yet recruitingThis study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo aims to shrink stomach tumors before surgery
Disease control Not yet recruitingThis study tests whether adding the drugs SHR-1701 and apatinib to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced stomach or gastroesophageal junction cancer. About 80 adults will be randomly assigned to receive either SHR-17…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
One-Time immune boost for ARID1A-Mutant cancers?
Disease control Not yet recruitingThis early-phase trial is testing whether a single dose of two immunotherapy drugs (tremelimumab and durvalumab) can increase cancer-fighting immune cells inside tumors. It includes 34 people with untreated, non-metastatic stomach or esophageal cancers that have an ARID1A gene mu…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThis phase 2 trial tests two different drug combinations given before surgery for people with a specific type of stomach cancer (dMMR/MSI-H). Participants will receive the immunotherapy drug adebrelimab plus either chemotherapy or another immunotherapy drug (SHR-8068). The goal i…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail aims to fight stomach cancer when first treatment fails
Disease control Not yet recruitingThis clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has wor…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Qingxia Li • Aim: Disease control
Last updated Jun 26, 2026 16:32 UTC
-
Glowing probe could help surgeons spot stomach cancer edges
Diagnosis Not yet recruitingThis study tests a new fluorescent dye that attaches to cancer cells, helping surgeons see exactly where a stomach tumor ends during surgery. The probe is tested on freshly removed stomach tissue from 32 patients. If successful, it could lead to more precise cancer removal and fe…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
Mind-Body link: emotional distress may influence cancer immunotherapy success
Knowledge-focused Not yet recruitingThis study looks at whether emotional distress before treatment affects how well immunotherapy works in people with locally advanced stomach or gastroesophageal junction cancer. Researchers will measure distress using questionnaires and track tumor response after surgery. The goa…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Could your sleep habits influence cancer treatment success?
Knowledge-focused Not yet recruitingThis study looks at whether sleep patterns—like duration, quality, and heart rate during sleep—are linked to how well stomach cancer responds to immunotherapy before surgery. Researchers will monitor sleep non-invasively in 120 patients with locally advanced gastric or gastroesop…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood test may let some stomach cancer patients skip harsh chemo
Knowledge-focused Not yet recruitingThis study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa g…
Matched conditions: GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Natera, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC